Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381810 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT00381810: Clinical Trial Phase 3 study, sponsored by Genentech.
NCT00381810 is a Phase 3 study that was terminated before completion, run by Genentech. The registered enrollment target is 31 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00381810, a Phase 3 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of response at 12 months. This study is open to participants previously enrolled in Genentech Study U2971g only.
Primary Outcome
A serious adverse event is defined as an adverse event that results in death, is life threatening, requires hospitalization, results in significant disability, results in birth defect, or is considered a significant medical event by the investigator.
Interventions
- DRUG Acetaminophen
- DRUG Rituximab
- DRUG Methylprednisolone
- DRUG Diphenhydramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-06-22 |
| Est. Completion | 2012-02-29 |
| Phase | Phase 3 |
Why NCT00381810 stopped before completion
NCT00381810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Acetaminophen is the first listed.
NCT00381810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00381810 about?
NCT00381810 is a clinical study titled "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus". This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of response at 12 months. This study is open to participants previously enrol...
What is the current status of trial NCT00381810?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2006-06-22. Estimated completion is 2012-02-29.
What interventions are being tested in trial NCT00381810?
The interventions under investigation include: Acetaminophen (DRUG), Rituximab (DRUG), Methylprednisolone (DRUG), Diphenhydramine (DRUG).
Who is sponsoring clinical trial NCT00381810?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00381810's enrollment target sits among peer trials
31 1914th of 2000 higher than 84 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI